sglt2 inhibitors vs glp 1 agonists View of Diabetes medications with cardiovascular protection after HARMONY Outcomes and DECLARE-TIMI 58: could metformin, pioglitazone, and long-acting GLP-1 receptor complement each other to save lives by different mechanisms? Metabolic Powerhouses: GLP-1 RAs and
Description
Table of Contents: How do Liraglutide and Semaglutide differ in their weight loss effects
PMCID: PMC10154650
Tamura, K., & Fujita, H
Diabetes Care (2021) 44(Suppl 1):S12
Cardiovascular outcome trials (CVOTs) of GLP-1RAs To date, the REWIND study has demonstrated for the first time that primary cardiovascular prevention strategies can significantly reduce cardiovascular adverse events in patients with T2DM, regardless of whether or not these patients are co-diagnosed with CVD [23]
